Diabetics who rely on glucose monitors are alarmed by recall linked to 7 deaths

Diabetics Relying on Glucose Monitors Face Concern Over Recall Tied to 7 Fatalities

Abbott, the medical equipment producer, has issued a recall for its FreeStyle Libre 3 and Libre 3 Plus glucose sensors, citing a risk of generating erroneous low readings. The company reported seven deaths and over 730 serious injuries globally, prompting alarm among users of the technology. For those who depend on these devices, the recall raises critical questions about the reliability of their health monitoring systems.

Michael Ford, a 68-year-old man with Type 2 diabetes, was cared for by his son Davonte, who managed his daily routines, including medication and blood sugar checks. One November morning, they were alerted by a low blood sugar message on Michael’s FreeStyle Libre 3 Plus sensor. Davonte followed medical advice, providing fast-acting carbs. However, he remained unaware that the reading was flawed, as Abbott would soon issue a warning about the sensors’ potential inaccuracies.

“My heart just dropped. Obviously, there’s a problem here,” Davonte said after realizing the monitor’s reading was incorrect.

Michael’s blood sugar continued to fluctuate, eventually dropping to 551 mg/dL when paramedics arrived. This level was more than triple what the device had indicated, leading to multiple cardiac arrests and his death the following day. Davonte has since filed a wrongful death lawsuit, alleging that the faulty readings were “catastrophically inaccurate.”

Diabetes, a condition affecting an estimated 40.1 million Americans, demands constant vigilance in monitoring blood sugar levels. While continuous glucose monitors offer convenience over traditional finger sticks, their malfunction poses significant risks. The Abbott recall has sparked at least three class-action lawsuits in the U.S., with additional cases pending in California, Washington, and North Carolina.

Patients and legal representatives are questioning whether the recall adequately covers all affected devices and if the actual number of injuries exceeds Abbott’s reported 860. Michael’s death, though linked to a recalled sensor, wasn’t included in the company’s tally because his specific serial number wasn’t flagged. Lindsy Delco, an Abbott spokesperson, stated the company takes all adverse events seriously, noting that not all sensors in the affected batches were impacted and not all incidents are tied to the recent recall.

Delco explained that the faulty readings were due to a production issue, which was resolved swiftly. Despite this, the incident has cast doubt on the safety of the technology. Dr. Amy Warriner, an endocrinologist and professor at the University of Alabama at Birmingham, called continuous glucose monitors a “complete game changer” when they were first introduced over two decades ago, offering a more efficient alternative to manual testing.